RT Journal Article
T1 Synovial Gene expression after Hemarthrosis differs between FVIII-deficient mice treated with recombinant FVIII or FVIII-Fc Fusion Protein
A1 Chumappumkal Joseph, Bilgimol
A1 Whisenant, Thomas C.
A1 Cooke, Esther J.
A1 Zhou, Jenny Y.
A1 Falah, Nicca
A1 De Pablo Moreno, Juan Andrés
A1 von Drygalski, Annette
AB To investigate if FVIII-Fc Fusion protein (FcFVIII) may modulate inflammation and immune stimulation in hemophilic synovium via the Fc-portion of immunoglobulin used for half-life extension we performed gene expression profiling in FVIII-deficient mice. Hemarthrosis was induced by sub-patellar puncture in FVIII-KO mice, + /- periprocedural recombinant human (rh)FVIII,murine (m)FcFVIII, or mIgG2a. Synovium was harvested at baseline and on days (D) 3 and 14, followed by RNA extraction and sequencing, and histological analysis. RNASeq data were processed using standard protocols followed by differential gene expression (DGE) analysis. Functional enrichment analysis generated molecular pathways (KEGG and Reactome). To distinguish between on-target and off-target (related and unrelated to injury/bleed) effects the following groups were compared: i) Baseline vs. injured-saline, ii) injured-saline vs. injured-rhFVIII, iii) injured-saline vs. injured-mFcFVIII. Knee injury in FVIII-KO mice resulted in hemarthrosis, which was prevented by peri-procedural rhFVIII and mFcFVIII treatments. Only a small proportion of genes was affected by FVIII treatment, exhibiting overlap but also distinct differences between both FVIII-preparations. Acutely (D3), mFcFVIII had unique on-target effects related to immune and inflammatory regulation, whereas rhFVIII mostly affected mRNA and protein processing. On day 14, macrophage profiling indicated a transition from M1 to M2, and only mFcFVIII uniquely influenced pathways and genes associated with tissue remodeling and repair. Some mFcFVIII DGE patterns resembled mIgG2a patterns. Synovial vascular remodeling and cartilage health were better with mFcFVIII than rhFVIII. Interestingly, both FVIII-preparations exerted off-target effects on immune system pathways, albeit with temporal differences. These observations provide proof-of-principle that the type of FVIII preparation can influence synovial processes beyond acute hemostasis control, deserving exploration in the setting of joint bleed control in hemophilia.
PB Public Library of Science (PLOS)
SN 1932-6203
YR 2025
FD 2025-05-19
LK https://hdl.handle.net/20.500.14352/122712
UL https://hdl.handle.net/20.500.14352/122712
LA eng
NO Chumappumkal Joseph, B., Whisenant, T. C., Cooke, E. J., Zhou, J. Y., Falah, N., De-Pablo Moreno, J. A., et al. (2025). Synovial Gene expression after Hemarthrosis differs between FVIII-deficient mice treated with recombinant FVIII or FVIII-Fc Fusion Protein. PLOS One, 20(5), e0320322. https://doi.org/10.1371/journal.pone.0320322
NO This study was funded by the National Hemophilia Foundation/Nicholas Cirelli Family Research Fund Judith Graham Pool Research Fellowship (EJC), by a research grant from Sanofi (AvD), and UL1TR001442 of CTSA (TCW). The funders had no role in study design, data collection, and analysis. Sanofi reviewed and provided feedback on the manuscript. The authors had full editorial control of the manuscript and provided their final approval of all content.Competing interests: AvD has received honoraria for participation in scientific advisory board panels and consulting for BioMarin, Pfizer, Bioverativ/Sanofi, CSL-Behring, Novo Nordisk, Spark Therapeutics, Takeda, and Regeneron. AvD is co-founder of Hematherix LLC, a biotech company developing superFVa therapy. This does not alter adherence to PLOS ONE policies on sharing data and materials.
NO National Hemophilia Foundation
NO Nicholas Cirelli Family Research Fund
NO Sanofi
NO Clinical and Translational Science Award
DS Docta Complutense
RD 30 dic 2025